Brown Advisory’s Amicus Therapeutics FOLD Stock Holding History

Brown Advisory’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$658K	Hold	45,525	–	–	﹤0.01%	973
2025 Q4	$648K	Hold	45,525	–	–	﹤0.01%	983
2025 Q3	$359K	Hold	45,525	–	–	﹤0.01%	1151
2025 Q2	$261K	Hold	45,525	–	–	﹤0.01%	1207
2025 Q1	$371K	Hold	45,525	–	–	﹤0.01%	1071
2024 Q4	$429K	Hold	45,525	–	–	﹤0.01%	1057
2024 Q3	$486K	Hold	45,525	–	–	﹤0.01%	1001
2024 Q2	$452K	Sell	45,525 -470	-1%	-$4.83K	﹤0.01%	975
2024 Q1	$542K	Buy	45,995 +10	+0%	+$128	﹤0.01%	923
2023 Q4	$653K	Hold	45,985	–	–	﹤0.01%	860
2023 Q3	$559K	Buy	45,985 +12,285	+36%	+$158K	﹤0.01%	880
2023 Q2	$423K	Hold	33,700	–	–	﹤0.01%	945
2023 Q1	$374K	Hold	33,700	–	–	﹤0.01%	981
2022 Q4	$411K	Sell	33,700 -806	-2%	-$9.07K	﹤0.01%	956
2022 Q3	$360K	Buy	34,506 +806	+2%	+$8.98K	﹤0.01%	930
2022 Q2	$362K	Hold	33,700	–	–	﹤0.01%	915
2022 Q1	$319K	Sell	33,700 -4	-0%	-$38	﹤0.01%	954
2021 Q4	$389K	Sell	33,704 -37	-0.1%	-$412	﹤0.01%	957
2021 Q3	$322K	Buy	33,741 +41	+0.1%	+$419	﹤0.01%	925
2021 Q2	$325K	Hold	33,700	–	–	﹤0.01%	925
2021 Q1	$333K	Sell	33,700 -2,506	-7%	-$38.8K	﹤0.01%	924
2020 Q4	$836K	Sell	36,206 -2,157	-6%	-$44.1K	﹤0.01%	686
2020 Q3	$542K	Sell	38,363 -494	-1%	-$7.2K	﹤0.01%	727
2020 Q2	$586K	Buy	38,857 +494	+1%	+$6.02K	﹤0.01%	694
2020 Q1	$354K	Hold	38,363	–	–	﹤0.01%	749
2019 Q4	$374K	Buy	+38,363	New	+$351K	﹤0.01%	828
2017 Q2	–	Sell	-31,850	Closed	-$227K	–	1228
2017 Q1	$227K	Sell	31,850 -304	-0.9%	-$1.92K	﹤0.01%	1068
2016 Q4	$160K	Buy	32,154 +304	+1%	+$2.1K	﹤0.01%	1092
2016 Q3	$236K	Hold	31,850	–	–	﹤0.01%	952
2016 Q2	$174K	Hold	31,850	–	–	﹤0.01%	995
2016 Q1	$269K	Hold	31,850	–	–	﹤0.01%	859
2015 Q4	$309K	Hold	31,850	–	–	﹤0.01%	790
2015 Q3	$446K	Hold	31,850	–	–	﹤0.01%	713
2015 Q2	$451K	Hold	31,850	–	–	﹤0.01%	654
2015 Q1	$347K	Hold	31,850	–	–	﹤0.01%	783
2014 Q4	$265K	Hold	31,850	–	–	﹤0.01%	827
2014 Q3	$190K	Hold	31,850	–	–	﹤0.01%	888
2014 Q2	$106K	Hold	31,850	–	–	﹤0.01%	922
2014 Q1	$66K	Hold	31,850	–	–	﹤0.01%	930
2013 Q4	$75K	Hold	31,850	–	–	﹤0.01%	885
2013 Q3	$74K	Hold	31,850	–	–	﹤0.01%	831
2013 Q2	$74K	Buy	+31,850	New	+$97.9K	﹤0.01%	802

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Brown Advisory's FOLD Position: Q1 2026 in Review

Brown Advisory held its Amicus Therapeutics (FOLD) position steady in Q1 2026 at 45,525 shares worth $658K. The position accounts for ﹤0.01% of the portfolio, ranked #973.

Brown Advisory first reported a position in FOLD in Q2 2013 and has held it in 42 quarters since. The position peaked at $836K in Q4 2020. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Brown Advisory held 45,525 shares of Amicus Therapeutics worth $658K as of Q1 2026.
Brown Advisory left its Amicus Therapeutics share count unchanged in Q1 2026.
Amicus Therapeutics made up ﹤0.01% of Brown Advisory's portfolio in Q1 2026, its #973 holding.
Brown Advisory first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 42 quarters since.
Brown Advisory's Amicus Therapeutics position peaked at $836K in Q4 2020.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Brown Advisory's 13F filing for Q1 2026, filed 15 May 2026.